ASTRO-Myovant Sciences-Pfizer Alliance New Combination Therapy Challenge

Sponsor Deadline: 

Jul 18, 2022



UI Contact: 

Sponsor link

To catalyze new collaborative research opportunities, and to facilitate radiation oncology leadership in scientific discovery with the Myovant Sciences-Pfizer Alliance in the space of multimodality combination therapy.

Challenge statement:

How can prostate cancer treatment be improved with the gonadotropinreleasing hormone (GnRH) receptor antagonist relugolix in patients receiving radiotherapy? Research proposals in the following topic areas are encouraged: • Use of relugolix with definitive radiotherapy (concomitant/adjuvant/neoadjuvant) in prostate cancer patients with High/Very-High Risk, Unfavorable Intermediate Risk, and Regional disease • Use of relugolix with radiotherapy as salvage therapy post treatment with curative intent • Concomitant treatment with other oral oncolytics (e.g., ARIs) • Synchronous oligometastatic/metastatic and oligoprogressive disease.

Studies of interest may include evaluating the following: • Clinical outcomes (i.e., rPFS, MFS, local control, etc.) • Testosterone kinetics • Patient-Reported Outcomes (PROs) • Safety/Adverse Events (AEs) • Compliance/adherence • Translational research such as exploratory biomarkers and mechanistic studies may be considered as part of a clinical trial.

Topic areas out-of-scope include: • Recurrent oligometastatic disease • Retrospective studies • All other tumor sites • Ex-US studies